Altimmune, Inc. (ALT): Price and Financial Metrics


Altimmune, Inc. (ALT): $9.05

-0.04 (-0.44%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ALT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ALT POWR Grades

  • Growth is the dimension where ALT ranks best; there it ranks ahead of 59.47% of US stocks.
  • The strongest trend for ALT is in Stability, which has been heading down over the past 178 days.
  • ALT ranks lowest in Stability; there it ranks in the 1st percentile.

ALT Stock Summary

  • Of note is the ratio of ALTIMMUNE INC's sales and general administrative expense to its total operating expenses; only 7.39% of US stocks have a lower such ratio.
  • For ALT, its debt to operating expenses ratio is greater than that reported by only 0.52% of US equities we're observing.
  • ALT's price/sales ratio is 137.13; that's higher than the P/S ratio of 98.03% of US stocks.
  • Stocks that are quantitatively similar to ALT, based on their financial statements, market capitalization, and price volatility, are MGNX, LPTX, CLLS, GRTS, and SYRS.
  • Visit ALT's SEC page to see the company's official filings. To visit the company's web site, go to altimmune.com.

ALT Valuation Summary

  • In comparison to the median Healthcare stock, ALT's price/sales ratio is 6630% higher, now standing at 134.6.
  • Over the past 209 months, ALT's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for ALT.

Stock Date P/S P/B P/E EV/EBIT
ALT 2022-11-25 134.6 2.2 -5.1 -3.7
ALT 2022-11-23 137.1 2.2 -5.2 -3.8
ALT 2022-11-22 137.9 2.2 -5.3 -3.8
ALT 2022-11-21 129.4 2.1 -4.9 -3.5
ALT 2022-11-18 130.9 2.1 -5.0 -3.5
ALT 2022-11-17 130.2 2.1 -5.0 -3.5

ALT Growth Metrics

    The 4 year cash and equivalents growth rate now stands at -92.66%.
  • Its year over year net income to common stockholders growth rate is now at -69.36%.
  • Its year over year price growth rate is now at -69.82%.
ALT's revenue has moved down $9,189,240 over the prior 52 months.

The table below shows ALT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 3.319658 -67.24694 -86.94232
2022-06-30 3.475217 -69.97215 -96.93701
2022-03-31 3.60484 -72.19478 -101.6567
2021-12-31 4.410356 -78.23794 -97.09082
2021-09-30 3.445404 -69.68439 -83.82328
2021-06-30 6.225836 -61.41412 -68.08273

ALT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ALT has a Quality Grade of D, ranking ahead of 13.22% of graded US stocks.
  • ALT's asset turnover comes in at 0.025 -- ranking 360th of 682 Pharmaceutical Products stocks.
  • OPTN, ENTA, and ELTP are the stocks whose asset turnover ratios are most correlated with ALT.

The table below shows ALT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.025 1 -0.839
2021-03-31 0.032 1 -0.867
2020-12-31 0.052 1 -0.992
2020-09-30 0.058 1 -1.332
2020-06-30 0.062 1 -1.567
2020-03-31 0.089 1 -1.191

ALT Price Target

For more insight on analysts targets of ALT, see our ALT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $30.86 Average Broker Recommendation 1.36 (Strong Buy)

ALT Stock Price Chart Interactive Chart >

Price chart for ALT

ALT Price/Volume Stats

Current price $9.05 52-week high $23.49
Prev. close $9.09 52-week low $3.83
Day low $8.95 Volume 591,400
Day high $9.47 Avg. volume 1,486,345
50-day MA $11.14 Dividend yield N/A
200-day MA $9.98 Market Cap 444.89M

Altimmune, Inc. (ALT) Company Bio


Altimmune, Inc., a clinical stage biopharmaceutical company, focused developing treatments for liver disease, immune modulating therapies, and vaccines. The company develops HepTcell, an immunotherapeutic product candidate that has completed Phase I clinical trial for patients chronically infected with the hepatitis B virus; NasoShield, an anthrax vaccine to provide for protection after a single intranasal administration; NasoVAX, a recombinant intranasal vaccine product candidate; and AdCOVID, a single-dose intranasal vaccine to protect against COVID-19 Its preclinical stage products include ALT-801, a novel peptide-based dual GLP-1/Glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis; and ALT-702, an investigational tumor immunostimulant for treating cancer. The company also develops veterinary product candidates. It has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.


ALT Latest News Stream


Event/Time News Detail
Loading, please wait...

ALT Latest Social Stream


Loading social stream, please wait...

View Full ALT Social Stream

Latest ALT News From Around the Web

Below are the latest news stories about ALTIMMUNE INC that investors may wish to consider to help them evaluate ALT as an investment opportunity.

Altimmune to Participate at Two Upcoming Investor Conferences

GAITHERSBURG, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences: Evercore ISI 5th Annual HealthCONx Virtual ConferenceTuesday, November 29, 2022Fireside chat at 10:55 am Eastern Time Piper Sandler 34th Annual Healthcare Conference in New York, NYThursday, December 1, 2022Fireside chat at 10:00 am Eastern Time The sess

Yahoo | November 22, 2022

Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), 89bio (ETNB) and Avadel Pharmaceuticals (AVDL)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Altimmune (ALT – Research Report), 89bio (ETNB – Research Report) and Avadel Pharmaceuticals (AVDL – Research Report) with bullish sentiments. Altimmune (ALT) In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Altimmune, with a price target of $50.00. The company's shares closed last Friday at $8.84. According to TipRanks.

Christine Brown on TipRanks | November 21, 2022

Altimmune Announces Third Quarter 2022 Financial Results and Provides a Business Update

Topline 24-week data from Phase 1b trial in subjects with non-alcoholic fatty liver disease (NAFLD) expected mid-December 2022 Interim 24-week readout from MOMENTUM Phase 2 obesity trial expected Q1 2023 GAITHERSBURG, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and nine months ended September 30, 2022, and provided a business update. “We continue on course in our advancement of p

Yahoo | November 10, 2022

B.Riley Financial Reaffirms Their Buy Rating on Altimmune (ALT)

In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Altimmune (ALT - Research Report), with a price target of $26.00. The company's shares closed yesterday at $11.65.Mamtani covers the Healthcare sector, focusing on stocks such as Altimmune, Novavax, and Intercept Pharma. According to TipRanks, Mamtani has an average return of -30.7% and a 20.11% success rate on recommended stocks. Currently, the analyst consensus on Altimmune is a Strong Buy with an average price target of $31.67, a 171.85% upside from current levels. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $28.00 price target.

Christine Brown on TipRanks | November 8, 2022

B.Riley Financial Sticks to Its Buy Rating for Altimmune (ALT)

In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Altimmune (ALT - Research Report), with a price target of $26.00. The company's shares opened today at $12.21.Mamtani covers the Healthcare sector, focusing on stocks such as Altimmune, Novavax, and Intercept Pharma. According to TipRanks, Mamtani has an average return of -30.4% and a 21.02% success rate on recommended stocks. Currently, the analyst consensus on Altimmune is a Strong Buy with an average price target of $31.67.

Christine Brown on TipRanks | November 4, 2022

Read More 'ALT' Stories Here

ALT Price Returns

1-mo -29.13%
3-mo -59.01%
6-mo 79.92%
1-year -11.79%
3-year 397.25%
5-year -83.33%
YTD -1.20%
2021 -18.79%
2020 496.83%
2019 -8.25%
2018 -96.55%
2017 -48.19%

Continue Researching ALT

Here are a few links from around the web to help you further your research on Altimmune Inc's stock as an investment opportunity:

Altimmune Inc (ALT) Stock Price | Nasdaq
Altimmune Inc (ALT) Stock Quote, History and News - Yahoo Finance
Altimmune Inc (ALT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5733 seconds.